Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement

28 Apr 2017

Abstract excerpt

Blinatumomab is a bispecific T-cell engaging αCD19 antibody used in refractory or relapsed B-cell precursor acute lymphoblastic leukemia (ALL). Recently, lineage switch to a myeloid phenotype has been described following CD19 targeting treatment in three pediatric patients with mixed lineage leukemia (MLL) rearranged ALL. We report the case of a female who received blinatumomab for a first relapse of ALL without...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to CAR-T cell therapy research
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28453885
DOI: 10.1002/pbc.26594

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangementPMID 28453885Read ↗

Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab TherapySemantic proximity Read ↗

CD19‐directed immunotherapy use in KMT2A‐rearranged acute leukemia: A case report and literature review of increased lymphoid to myeloid lineage switchSemantic proximity Read ↗

Extramedullary relapse of KMT2A(MLL)-rearranged acute lymphoblastic leukemia with lineage switch following blinatumomabSemantic proximity Read ↗

Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.Semantic proximity Read ↗

Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapySemantic proximity Read ↗

Multi-courses of Blinatumomab combined with reduced dose chemotherapy has been successfully used in chemo intolerant middle to high-risk pediatric B-ALL patients with invasive fungal diseaseSemantic proximity Read ↗

Lineage Switch in an Infant B-Lymphoblastic Leukemia With t(1;11)(p32;q23); KMT2A/EPS15 , Following Blinatumomab TherapySemantic proximity Read ↗

CRLF2 -rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapySemantic proximity Read ↗

Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantationSemantic proximity Read ↗

To B‐ or not to B‐: A review of lineage switched acute leukemiaSemantic proximity Read ↗

Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysisSemantic proximity Read ↗

CD19 negative and dim precursor B-lineage acute lymphoblastic leukemias: real-world challenges in a targeted-immunotherapy eraSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.